Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Multiple Myeloma 23Recurrence 3Neoplasms, Plasma Cell 2Lymphoma 2beta-Thalassemia 1Thalassemia 1Sarcoma, Myeloid 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Neoplasms 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphadenopathy 1Leukemia, Myeloid, Acute 1HIV Infections 1Anemia, Sickle Cell 1

Interventions

Rituximab 12Biopsy 12Specimen Handling 11Cyclophosphamide 11Magnetic Resonance Spectroscopy 10obinutuzumab 7Lenalidomide 7fludarabine 6Prednisone 6pembrolizumab 5Nuclear Medicine Department, Hospital 5X-Rays 4Doxorubicin 4venetoclax 3ibrutinib 3glofitamab 3fludarabine phosphate 3acalabrutinib 3Vincristine 3Tacrolimus 3Mycophenolic Acid 3GSK2636771 3Etoposide 3Busulfan 3Bendamustine Hydrochloride 3zanubrutinib 2trametinib 2tocilizumab 2palbociclib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × Bortezomib × 30 days × Clear all
NCT01415752 2026-06-03

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
373 enrolled 14 charts
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT04915248 2026-06-02

FIL_DALYA

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting
28 enrolled
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡